GE HealthCare has delivered the initial subject doses of a positron emission tomography (PET) myocardial perfusion imaging ...
The U.S. FDA’s approval of Telix Pharmaceuticals Ltd.’s kit for preparing prostate-specific membrane antigen-PET imaging for prostate cancer ... The FDA’s nod for the imaging agent, TLX007-CDx, now ...
Gozellix builds on the success of Telix’s established PSMA-PET imaging agent, Illuccix, and will be available alongside the first-generation product, providing choice for customers and patients based ...
MELBOURNE, Australia, Feb. 24, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today announces that its prostate cancer PET [1] imaging agent ...